Japanese Organization for Medical Device Development, Inc. (JOMDD; CEO: Takahiro Uchida, Tokyo, JAPAN) has closed a licensing deal with USCI Japan, Inc. (CEO: Kiyotaka Mori, Tokyo, Japan)
Aortic Valve Reconstruction surgery is a new surgical technique for aortic regurgitation and aortic stenosis. Unlike the conventional valve replacement of implanting a prosthetic valve, this surgery is to treat damaged aortic valve with patient’s own pericardium or an equivalent material. Our new device will play an important role during this new surgery. The device that JOMDD developed determines the size and shape of each leaflet of the valve to be reconstructed.
According to Professor Ozaki, “it does not require anti-coagulant therapy (such as warfarin) for post mechanical valve replacement surgery, and as compared with the biological valve, it is possible to achieve the excellent long-term results owing to the low-impact physiological/native movement of the base of the valve system (valve annulus).”
>>Road to Commercialization : OZAKI VRecS™
Due to the increasing demand from a number of hospitals all over Japan for this new surgical procedure and the device, OZAKI VRecS™, in order to spread the clinical benefits of this new technique and accelerate the widespread adoption of this device, JOMDD has completed the licensing deal with USCI Japan, which has significant strength in marketing and sales of medical devices in Japan.
JOMDD will continue promoting OZAKI VRecS™ outside Japan, and the business of incubating other medical device seeds/technologies candidates.
■Licensing of the domestic use of OZAKI VRecS™
Date: 2014/8/22
■Current status and future development of OZAKI VRecS™ in Japan
As described above, USCI Japan, Inc. will be responsible for the domestic business of OZAKI VRecS™ and JOMDD will continuously make substantial contributions promoting the OZAKI VRecS™ world wide.
The OZAKI VRecS™ just received a great deal of responses during the luncheon seminar at the 67th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery October 1st, 2014.
JOMDD will continue to help achieve greater name recognition with the goal more hospitals adopt this device, leading to aortic valve reconstruction surgery as the de facto standard treatment in aortic valve stenosis and aortic insufficiency.
■Profile of USCI Japan
Company Name : USCI Japan, Inc.
URL ： http://www.usciholdings.com/english/
Address : AS-4 Building, 2-27-11 Yoyogi, Shibuya-ku, Tokyo
Date of Foundation : April, 1999
CEO : Kiyotaka Mori
Core Business : importing, manufacturing and selling medical devices
